Roche ends Alzheimer’s partnership with AC Immune after lackluster data

Roche and Genentech have ended a nearly two-decade Alzheimer’s disease partnership with Swiss biotech AC Immune after numerous setbacks and cloudy data.

The collaboration involved working together on two Alzheimer’s programs, crenezumab and semorinemab, that will both be returned to AC Immune, the biotech said in a Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks